title: Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
abstract: Blood pressure (BP) is monitored and managed to prevent cardiovascular complications of hypertension, but BP variability (BPV) has not been sufficiently studied. This analysis assessed whether patients receiving amlodipine vs other antihypertensive agents had lower BPV after ≥12 weeks of treatment. Studies were included if individual subject data were available, had ≥1 active comparator, and treatment duration was ≥12 weeks. BPV was assessed using standard deviation (SD) and coefficient of variation (CV) of systolic BP across visits from 12 weeks. Individual trial and meta-analyses were performed for SD- and CV-based methodology. Five studies (47,558 BPV-evaluable patients) were included. Patient characteristics were largely consistent across the studies, but BP measurements varied from ∼4 months to ∼6 years. BPV with amlodipine was significantly (P < .0001) lower vs atenolol and lisinopril; significantly (P < .0001) lower than enalapril in one study and numerically, but not significantly lower in another; and similar to chlorthalidone and losartan. Meta-analysis revealed a treatment difference (standard error) for amlodipine vs all active comparators of -1.23 (0.46; P = .008) mm Hg using SD and -0.86 (0.31; P = .005) using CV. These findings suggest that amlodipine is effective for minimizing BPV. Future studies need to confirm a causal link between BPV and cerebrovascular/cardiovascular outcomes.
authors.affiliation: Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address: jiguangwang@aim.com.
authors.forename: Ji-Guang
authors.initials: JG
authors.lastname: Wang
authors.affiliation: Pfizer Research and Development Center, Shanghai, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Yan
authors.affiliation: Pfizer Inc, New York, NY, USA.
authors.forename: Barrett W
authors.initials: BW
authors.lastname: Jeffers
mesh_terms: D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002752:Chlorthalidone / Q000627:therapeutic use; D004656:Enalapril / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017706:Lisinopril / Q000627:therapeutic use; D019808:Losartan / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
chemical_list: D000959:Antihypertensive Agents; D017311:Amlodipine; D001262:Atenolol; D004656:Enalapril; D017706:Lisinopril; D019808:Losartan; D002752:Chlorthalidone
keywords: Blood pressure variability; calcium channel blockers; hypertension; meta-analysis; trial